Teclistamab-Daratumumab in AL Amyloidosis
Teclistamab-Daratumumab in AL Amyloidosis
Recruiting · NCT07110844 · Registry updated 2026-07-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Teclistamab-Daratumumab in AL Amyloidosis | Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, proteostasis deficiencies | Recruiting | Phase 2 | 2026-07-13 | NCT07110844 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Janssen Pharmaceuticals | 24 |
| Rajshekhar Chakraborty, MD | 1 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Boston Medical Center | Boston | United States | 200 |
| Columbia University Irving Medical Center | New York | United States | 234 |
| Medical College of Wisconsin | Milwaukee | United States | 483 |